For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with Celgene in one of the biggest acquisitions in pharmaceutical history, the company’s treasury team needed to regroup. BMS had become significantly more complex, yet treasury needed to be faster and more agile than ever before to meet the future demands of the enterprise.

When Sandra Ramos-Alves became senior vice president and treasurer of BMS in 2021, innovation was a top priority. Her philosophy revolved around building trust and a continuous improvement mindset, encouraging treasury staff to perpetually challenge and rethink their ways of working. Today, BMS treasury is always on the lookout for better approaches to everything from cash forecasting, interest rate hedging, and foreign exchange (FX) risk management to optimizing its captive insurance structure.